Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Nuvation Bio Inc. presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The company's CEO, David Hung, discussed their pipeline, including the recently approved drug IBTROZI for non-small cell lung cancer. The presentation highlighted the company's ongoing efforts and future plans in the biotech sector.
- ▪Nuvation Bio Inc. presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
- ▪CEO David Hung provided an overview of the company's pipeline and recent achievements.
- ▪The drug IBTROZI, a ROS1 inhibitor, was approved in July 2025 and has seen three quarters of launch.
2 outlets in our directory ran this story, first to last over 2 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
Seeking Alpha files mainly under finance. We currently carry 6,317 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908208-nuvation-bio-inc-nuvb-presents-at-h-c-wainwright-4th-annual-bioconnect-investor-conference"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
